Diabetes Treatment Strategies and Patient Outcomes

Diabetes management has evolved from a one-size-fits-all approach to a nuanced, stratified system that integrates lifestyle intervention, pharmacotherapy and emerging technologies. Core strategies begin with diet modification and structured exercise, often augmented by metformin as a first-line agent for type 2 diabetes. Subsequent therapeutic intensification may involve insulin regimens tailored to basal, prandial or mixed profiles, or add-on agents such as dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors. Each class targets distinct aspects of glucose homeostasis, from enhanced insulin secretion to reduced renal glucose reabsorption. Treatment choice is guided by glycaemic control, comorbidity profile and patient preference, with particular attention to cardiovascular and renal protection. Recent years have seen greater emphasis on quality of life, adherence and the use of digital health tools, including telemedicine and decision-support algorithms. Outcomes are assessed by both hard end points—such as reductions in micro- and macrovascular complications—and patient-reported measures of satisfaction, treatment burden and functional capacity. This holistic framework underscores the global imperative to deliver patient-centred care that balances efficacy, safety and individual circumstances.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Diabetes Treatment Strategies and Patient Outcomes publication trend

The graph below shows the total number of articles in diabetes treatment strategies and patient outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Glycaemic control: The maintenance of blood glucose levels within a target range to minimise risk of acute and chronic complications.

HbA1c: Glycated haemoglobin, a measure of average blood glucose over the previous two to three months, expressed as a percentage.

SGLT2 inhibitor: A class of oral agent that lowers blood glucose by blocking renal glucose reabsorption, promoting urinary excretion.

GLP-1 receptor agonist: A peptide analogue that mimics endogenous glucagon-like peptide-1 to enhance insulin secretion and suppress glucagon release, often with weight-loss benefits.

Machine learning: A subset of artificial intelligence that uses statistical algorithms to identify patterns in data, enabling prediction and decision support in clinical settings.

References

1. Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study). Diabetology & Metabolic Syndrome (2018).
2. Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study. Diabetology & Metabolic Syndrome (2017).
3. Machine Learning Approach to Decision Making for Insulin Initiation in Japanese Patients With Type 2 Diabetes (JDDM 58): Model Development and Validation Study. JMIR Medical Informatics (2021).